Zev A. Wainberg, MD

Zev A. Wainberg, MD, discusses current available frontline chemotherapy regimens for patients with metastatic pancreatic cancer.

Zev A. Wainberg, MD, MSc, outlines factors informing his choice between standard frontline chemotherapy regimens in metastatic pancreatic cancer.

Yelena Y. Janjigian, MD, and Zev A. Wainberg, MD, discuss ongoing trials that could help refine the gastric/GEJ cancer treatment paradigm.

Yelena Y. Janjigian, MD, and Zev A. Wainberg, MD, discuss other key gastric cancer data presented at the 2025 ESMO Congress.

Yelena Y. Janjigian, MD, and Zev A. Wainberg, MD, discuss the potential clinical implications of the investigation of domvanalimab plus zimberelimab and FOLFOX in gastric/GEJ/esophageal adenocarcinoma.

Yelena Y. Janjigian, MD, and Zev A. Wainberg, MD, detail the design of the phase 3 STAR-221 trial comparing domvanalimab plus zimberelimab and FOLFOX with nivolumab plus chemotherapy for first-line advanced gastric, GEJ, or esophageal adenocarcinoma. They discuss why nivolumab plus chemotherapy serves as an appropriate control arm and the importance of head-to-head evidence in clarifying comparative benefit across immunotherapy combinations. They review the study’s primary endpoints and overall goals, including survival outcomes and the potential to redefine the frontline standard.

Yelena Y. Janjigian, MD, and Zev A. Wainberg, MD, discuss the implications of findings from the phase 2 EDGE-Gastric trial.

Yelena Y. Janjigian, MD, and Zev A. Wainberg, MD, discuss current treatment standards in advanced gastric/GEJ cancer.

Leading experts across oncology specialties preview the key studies and data they are most anticipating ahead of the 2025 ESMO Congress.

Zev A. Wainberg, MD, MSc, highlighted notable research in gastric cancer and cholangiocarcinoma presented during the 2025 ESMO GI Congress.

Zev A. Wainberg, MD, MSc, discusses data from the EDGE-Gastric trial of domvanalimab plus zimberelimab and FOLFOX in first-line, metastatic gastric cancer.

Zev A. Wainberg, MD, discusses findings from the phase 2/3 ASPEN-06 trial (NCT05002127) of evorpacept plus trastuzumab, ramucirumab, and paclitaxel in HER2-overexpressing gastric/GEJ cancer.

Dr Wainberg discusses the FDA approval of first-line NALIRIFOX for patients with metastatic pancreatic adenocarcinoma.

Zev A. Wainberg, MD, discusses the FDA approval of NALIRIFOX for patients with metastatic pancreatic ductal adenocarcinoma.

Zev A. Wainberg, MD, discusses the rationale behind the phase 3 NAPOLI 3 trial in patients with metastatic pancreatic ductal adenocarcinoma.

Zev A. Wainberg, MD, discusses the evaluation of liposomal irinotecan plus 5-fluorouracil leucovorin, and oxaliplatin vs nab-paclitaxel plus gemcitabine in the phase 3 NAPOLI 3 trial in patients with metastatic pancreatic ductal adenocarcinoma.

Zev A. Wainberg, MD, discusses standard frontline treatment approaches for patients with metastatic esophageal squamous cell carcinoma and highlights data supporting the use of tislelizumab in combination with chemotherapy in ESCC.

Zev A. Wainberg, MD, discusses the importance of enrolling patients with colorectal cancer to clinical trials, despite the difficulties caused by COVID-19.

A brief discussion regarding current data and interest in treating appropriate patients with metastatic colorectal cancer with potent KRAS G12C selective inhibitors.

Drs Jaffer A. Ajani and Zev A. Wainberg comment on current obstacles surrounding the treatment of metastatic colorectal cancer and consider the future use of ctDNA as more is learned about the disease.

Best practices for managing skin rashes associated with anti-EGFR therapy for metastatic colorectal cancer.

Recommendations for treating patients with relapsed/refractory metastatic colorectal cancer in the third-line or later settings with regorafenib or TAS-102 therapy.

The importance of aligning second-line treatment decisions with patient goals in metastatic colorectal cancer, and the benefits of treating patients with biweekly cetuximab, especially during the COVID-19 pandemic.

Reactions to recent changes approved by the FDA to the dosing schedule of cetuximab for metastatic colorectal cancer and the value of real-word data on clinical practice patterns in the community when administering this drug.

Treatment approaches available for patients with newly diagnosed metastatic colorectal cancer that is RAS wild type and factors that impact decisions for utilizing a 2-drug versus 3-drug regimen.

Drs Jaffer A. Ajani and Zev A. Wainberg comment on the rationale for conducting full next-generation sequencing panels on patients with metastatic colorectal cancer and explain how to best utilize information provided to inform treatment decisions.

The significance of studying genomics in metastatic colorectal cancer and an overview of actionable targets that can be tested for to help in treatment decisions for newly diagnosed disease.

Dr Jaffer A. Ajani highlights the increasing incidence of colorectal cancer diagnoses in younger patients as a growing concern during a discussion on trends in prevalence.

Zev A. Wainberg, MD, discusses optimal dosing with regorafenib in colorectal cancer.

Zev A. Wainberg, MD, discusses the potential role of neoadjuvant chemotherapy in pancreatic cancer.